Latest Breaking News On - Hematopoietic cell transplantation - Page 10 : vimarsana.com

Bristol Myers Squibb Presents New Data at ASH 2023 Demonstrating Clinical Benefit Across B-cell Malignancies with Breyanzi as a Second-Line Treatment in High-Risk Follicular Lymphoma and in Relapsed or Refractory Chronic Lymphocytic Leukemia

PRINCETON, N.J. (BUSINESS WIRE) Dec 10, 2023

United statesFranck morschhauserBristol myers squibbmediaBristol myers squibbAnne kerberTanya siddiqiExchange commissionInternational workshop on chronic lymphocytic leukemiaCity of hope national medical centerDepartment of hematologyAmerican society of hematologyHead of late clinical developmentDrug administrationMyers squibbOral presentationAnnual meeting

Orca-T Demonstrates Feasibility in Older Patients With Hematologic Malignancies

The use of Orca-T with myeloablative chemotherapy conditioning had comparable safety and efficacy to that of standard allogeneic transplant in younger and older patients with hematologic malignancies, according to data from a phase 1b study.

United statesUniversity of california los angelesBone marrow transplantation stem cell processing centerJonsson comprehensive cancer centerCalifornia los angelesHematopoietic cell transplantationComorbidity indexOrca tHematologic malignanciesAsh annual meetingAllogeneic transplantCaspianh oliaiJonsson comprehensive cancer centerUniversity of california los angeles

TScan Therapeutics Presents Initial Phase 1 Clinical

TScan Therapeutics Presents Initial Phase 1 Clinical
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

United statesHeather savelleMonzrm al malkiDebora bartonGavin macbeathJoyce allaireAl malkiTscan therapeutics incGlobe newswire tscan therapeutics incLifesci advisorsAmerican society of hematologyDepartment of hematology hematopoietic cell transplantationSecurities exchangeAmerican societyAnnual meetingChief medical

TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition

TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesMonzrm al malkiHeather savelleDebora bartonGavin macbeathAl malkiJoyce allaireDepartment of hematology hematopoietic cell transplantationGlobe newswire tscan therapeutics incLifesci advisorsAmerican society of hematology annual meetingTscan therapeutics incAmerican society of hematologySecurities exchangeTherapeutics presents initial phaseAmerican society

Brexu-Cel Induces Responses in Real-World Population of High-Risk R/R MCL

Brexucabtagene autoleucel is safe and effective in real-world patients with relapsed/refractory mantle cell lymphoma, regardless of the presence of high-risk features.

United statesSwetha kambhampatiMantle cell lymphoma international prognostic indexMarrow transplant researchDivision of lymphomaInternational bloodDepartment of hematologyHematopoietic cell transplantationPublished julyBrexucabtagene autoleucelPatients with relapsed refractory mantle cell lymphomaZuma 2 trialCity of hope